Related references
Note: Only part of the references are listed.Systemic Administration of Reovirus (Reolysin) Inhibits Growth of Human Sarcoma Xenografts
Pooja Hingorani et al.
CANCER (2011)
Preclinical Evaluation of Telomerase-Specific Oncolytic Virotherapy for Human Bone and Soft Tissue Sarcomas
Tsuyoshi Sasaki et al.
CLINICAL CANCER RESEARCH (2011)
Oncolytic vaccinia virus for the treatment of cancer
Kilian Guse et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Immunotherapeutic potential of oncolytic vaccinia virus
Steve H. Thorne
IMMUNOLOGIC RESEARCH (2011)
Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus
Guidong Li et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Oncolytic Vesicular Stomatitis Virus Administered by Isolated Limb Perfusion Suppresses Osteosarcoma Growth
Tadahiko Kubo et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2011)
Vesicular Stomatitis Virus Has Extensive Oncolytic Activity against Human Sarcomas: Rare Resistance Is Overcome by Blocking Interferon Pathways
Justin C. Paglino et al.
JOURNAL OF VIROLOGY (2011)
Oncolytic Adenoviruses for the Treatment of Human Cancer: Focus on Translational and Clinical Data
Sari Pesonen et al.
MOLECULAR PHARMACEUTICS (2011)
Targeting Tumor Vasculature With an Oncolytic Virus
Caroline J. Breitbach et al.
MOLECULAR THERAPY (2011)
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
Tae-Ho Hwang et al.
MOLECULAR THERAPY (2011)
Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer
Jun Li et al.
MOLECULAR THERAPY (2011)
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Caroline J. Breitbach et al.
NATURE (2011)
Cancer Stem Cell-Like Cells Derived from Malignant Peripheral Nerve Sheath Tumors
Melanie Spyra et al.
PLOS ONE (2011)
Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients
Vincenzo Cerullo et al.
CANCER RESEARCH (2010)
Novel targeted therapies in the treatment of soft-tissue sarcomas
Joseph Chao et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Past, present and future of therapies in pediatric sarcomas
Pooja Hingorani et al.
FUTURE ONCOLOGY (2010)
Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?
Ryuichi Kanai et al.
FUTURE ONCOLOGY (2010)
VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy
F. K. Eshun et al.
GENE THERAPY (2010)
Intravenous administration of ReolysinA®, a live replication competent RNA virus is safe in patients with advanced solid tumors
Radharani Gollamudi et al.
INVESTIGATIONAL NEW DRUGS (2010)
Molecular engineering and validation of an oncolytic herpes simplex virus type transcriptionally targeted to midkine-positive tumors
Arturo R. Maldonado et al.
JOURNAL OF GENE MEDICINE (2010)
Type I Interferon-Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy
Subbiah Elankumaran et al.
JOURNAL OF VIROLOGY (2010)
Targeting Localized Immune Suppression Within the Tumor Through Repeat Cycles of Immune Cell-oncolytic Virus Combination Therapy
Stephen H. Thorne et al.
MOLECULAR THERAPY (2010)
A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors
John Nemunaitis et al.
MOLECULAR THERAPY (2010)
Current Issues and Future Directions of Oncolytic Adenoviruses
Masato Yamamoto et al.
MOLECULAR THERAPY (2010)
Oncolytic Virotherapy Reaches Adolescence
Adrienne M. Hammill et al.
PEDIATRIC BLOOD & CANCER (2010)
Initial Testing of the Replication Competent Seneca Valley Virus (NTX-010) by the Pediatric Preclinical Testing Program
Christopher L. Morton et al.
PEDIATRIC BLOOD & CANCER (2010)
Cancer Stem Cells: Controversial or Just Misunderstood?
Craig T. Jordan
CELL STEM CELL (2009)
Buy One Get One Free: Armed Viruses for the Treatment of Cancer Cells and their Microenvironment
Balveen Kaur et al.
CURRENT GENE THERAPY (2009)
Silica xerogels as pharmaceutical drug carriers
David Quintanar-Guerrero et al.
EXPERT OPINION ON DRUG DELIVERY (2009)
Herpes Simplex Virus Oncolytic Therapy for Pediatric Malignancies
Gregory K. Friedman et al.
MOLECULAR THERAPY (2009)
Targeting Cancer-initiating Cells With Oncolytic Viruses
Timothy P. Cripe et al.
MOLECULAR THERAPY (2009)
Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy
Candice Willmon et al.
MOLECULAR THERAPY (2009)
Neuroblastoma Cell Lines Contain Pluripotent Tumor Initiating Cells That Are Susceptible to a Targeted Oncolytic Virus
Yonatan Y. Mahller et al.
PLOS ONE (2009)
Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation
Fabian Benencia et al.
CANCER BIOLOGY & THERAPY (2008)
Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors
Yonatan Y. Mahller et al.
CANCER RESEARCH (2008)
Oncolytic Semliki Forest Virus Vector as a Novel Candidate against Unresectable Osteosarcoma
Anna Ketola et al.
CANCER RESEARCH (2008)
Enhancing poxvirus oncolytic effects through increased spread and immune evasion
David H. Kirn et al.
CANCER RESEARCH (2008)
A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
Laura Vidal et al.
CLINICAL CANCER RESEARCH (2008)
Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity
Robin J. Prestwich et al.
CLINICAL CANCER RESEARCH (2008)
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus
Jian Qiao et al.
CLINICAL CANCER RESEARCH (2008)
Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy
Katie Twigger et al.
CLINICAL CANCER RESEARCH (2008)
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors
Yushui Wu et al.
CLINICAL CANCER RESEARCH (2008)
Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall
Armita Bahrami et al.
MODERN PATHOLOGY (2008)
Intravenous administration of the conditionally replicative adenovirus Ad5-Δ24RGD induces regression of osteosarcoma lung metastases
Harm C. A. Graat et al.
MOLECULAR CANCER (2008)
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Byeong-Ho Park et al.
LANCET ONCOLOGY (2008)
Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide
Mark A. Currier et al.
MOLECULAR THERAPY (2008)
Pediatric nonrhabdomyosarcoma soft tissue sarcomas
Sheri L. Spunt et al.
ONCOLOGIST (2008)
Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus
David H. Kirn et al.
PLOS MEDICINE (2007)
Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus
Lalita Wadhwa et al.
CANCER RESEARCH (2007)
Seneca valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers
P. Seshidhar Reddy et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
Steve H. Thorne et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Gene therapy clinical trials worldwide to 2007 - an update
Michael L. Edelstein et al.
JOURNAL OF GENE MEDICINE (2007)
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow
Caroline J. Breitbach et al.
MOLECULAR THERAPY (2007)
Use of reverse genetics to enhance the oncolytic properties of newcastle disease virus
Adam Vigil et al.
CANCER RESEARCH (2007)
Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas
M. Lae et al.
JOURNAL OF PATHOLOGY (2007)
Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma
J. Hannay et al.
GENE THERAPY (2007)
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model
Yonatan Y. Mahller et al.
MOLECULAR THERAPY (2007)
Stem cell collection and gene transfer in Fanconi anemia
Patrick F. Kelly et al.
MOLECULAR THERAPY (2007)
Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma
Dennis Hoffmann et al.
HUMAN GENE THERAPY (2007)
Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma
Hongtao Li et al.
CLINICAL CANCER RESEARCH (2007)
Clinical trials with oncolytic adenovirus in China
Wang Yu et al.
CURRENT CANCER DRUG TARGETS (2007)
Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors
Ta-Chiang Liu et al.
CLINICAL CANCER RESEARCH (2006)
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Giulia Fulci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Synergistic antitumor effects of immune cell-viral biotherapy
SH Thorne et al.
SCIENCE (2006)
Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy
Y Ino et al.
CLINICAL CANCER RESEARCH (2006)
Recent progress in the battle between oncolytic viruses and tumours
KA Parato et al.
NATURE REVIEWS CANCER (2005)
Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma
F Benencia et al.
HUMAN GENE THERAPY (2005)
Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses
MA Currier et al.
CANCER GENE THERAPY (2005)
Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas
E Galanis et al.
GENE THERAPY (2005)
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells
MR Verneris et al.
BLOOD (2004)
Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses
S Sugiura et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2004)
Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus
SH Thorne et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2004)
Reovirus oncolysis: The Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection
KL Norman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells:: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv
T Korn et al.
JOURNAL OF GENE MEDICINE (2004)
Oncolytic measles viruses for cancer therapy
T Nakamura et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2004)
Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer
O Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
Oncolytic herpes simplex virus vectors for cancer virotherapy
S Varghese et al.
CANCER GENE THERAPY (2002)
Ewing sarcoma family of tumors express adenovirus receptors and are susceptible to adenovirus-mediated oncolysis
AM Rice et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2002)
Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene
TM Pawlik et al.
CANCER (2002)
Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses
NS Bharatan et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2002)
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers
AL Pecora et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
DGR Evans et al.
JOURNAL OF MEDICAL GENETICS (2002)
Phase I trial of intraperitoneal injection of the E1B-55-kd-Gene -: Deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer
PA Vasey et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
A mitogenic signal triggered at an early stage of vaccinia virus infection - Implication of MEK/ERK and protein kinase in a virus multiplication
JC de Magalhaes et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates
S Varghese et al.
HUMAN GENE THERAPY (2001)
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity
J Nemunaitis et al.
GENE THERAPY (2001)
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
KD Fisher et al.
GENE THERAPY (2001)
The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells
GA Mashour et al.
ONCOGENE (2001)
Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?
D Kirn
GENE THERAPY (2001)
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
FR Khuri et al.
NATURE MEDICINE (2000)
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
DF Stojdl et al.
NATURE MEDICINE (2000)
Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer
T Hermiston
JOURNAL OF CLINICAL INVESTIGATION (2000)
Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant
M Puhlmann et al.
CANCER GENE THERAPY (2000)
Share Paper
